Simris Alg AB (publ) (SIMRIS-B.ST)
SEK 0.07
(-1.75%)
SEK 0.07
(-1.75%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 148.93 Million SEK | -8.45% |
| 2022 | 162.67 Million SEK | 1381.58% |
| 2021 | 10.98 Million SEK | 13.88% |
| 2020 | 9.64 Million SEK | -43.98% |
| 2019 | 17.21 Million SEK | 71.18% |
| 2018 | 10.05 Million SEK | -14.11% |
| 2017 | 11.7 Million SEK | 6.13% |
| 2016 | 11.02 Million SEK | -34.9% |
| 2015 | 16.94 Million SEK | 1461.47% |
| 2014 | 1.08 Million SEK | 54.44% |
| 2013 | 702.51 Thousand SEK | 10.93% |
| 2012 | 633.3 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 158.22 Million SEK | 2.94% |
| 2024 Q1 | 153.7 Million SEK | 3.2% |
| 2023 Q4 | 148.93 Million SEK | -10.61% |
| 2023 Q3 | 166.62 Million SEK | -9.29% |
| 2023 Q1 | 169.84 Million SEK | 4.41% |
| 2023 Q2 | 183.68 Million SEK | 8.15% |
| 2023 FY | 148.93 Million SEK | -8.45% |
| 2022 FY | 162.67 Million SEK | 1381.58% |
| 2022 Q4 | 162.67 Million SEK | 5.14% |
| 2022 Q3 | 154.73 Million SEK | 2283.78% |
| 2022 Q2 | 6.49 Million SEK | -53.42% |
| 2022 Q1 | 13.93 Million SEK | 26.92% |
| 2021 Q2 | 8.85 Million SEK | 6.81% |
| 2021 Q3 | 12.22 Million SEK | 38.01% |
| 2021 FY | 10.98 Million SEK | 13.88% |
| 2021 Q1 | 8.29 Million SEK | -13.98% |
| 2021 Q4 | 10.98 Million SEK | -10.19% |
| 2020 Q3 | 11.3 Million SEK | -48.93% |
| 2020 Q2 | 22.14 Million SEK | 33.89% |
| 2020 FY | 9.64 Million SEK | -43.98% |
| 2020 Q4 | 9.64 Million SEK | -14.74% |
| 2020 Q1 | 16.54 Million SEK | -3.89% |
| 2019 Q3 | 26.97 Million SEK | 34.0% |
| 2019 FY | 17.21 Million SEK | 71.18% |
| 2019 Q4 | 17.21 Million SEK | -36.19% |
| 2019 Q2 | 20.12 Million SEK | 41.25% |
| 2019 Q1 | 14.25 Million SEK | 41.73% |
| 2018 Q4 | 10.05 Million SEK | -48.33% |
| 2018 FY | 10.05 Million SEK | -14.11% |
| 2018 Q1 | 12.4 Million SEK | 5.95% |
| 2018 Q2 | 15.6 Million SEK | 25.8% |
| 2018 Q3 | 19.45 Million SEK | 24.72% |
| 2017 Q4 | 11.7 Million SEK | 16.88% |
| 2017 FY | 11.7 Million SEK | 6.13% |
| 2017 Q1 | 11.37 Million SEK | 3.1% |
| 2017 Q2 | 10.68 Million SEK | -6.02% |
| 2017 Q3 | 10.01 Million SEK | -6.28% |
| 2016 Q2 | 14.56 Million SEK | 195.4% |
| 2016 FY | 11.02 Million SEK | -34.9% |
| 2016 Q1 | 4.93 Million SEK | -70.89% |
| 2016 Q4 | 11.02 Million SEK | -27.53% |
| 2016 Q3 | 15.21 Million SEK | 4.46% |
| 2015 Q4 | 16.94 Million SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | 16.94 Million SEK | 1461.47% |
| 2014 FY | 1.08 Million SEK | 54.44% |
| 2013 FY | 702.51 Thousand SEK | 10.93% |
| 2012 FY | 633.3 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | -39.723% |
| Ziccum AB (publ) | 6.38 Million SEK | -2231.528% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -6213.607% |
| BioArctic AB (publ) | 139.5 Million SEK | -6.763% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -330.419% |
| Mendus AB (publ) | 51.22 Million SEK | -190.753% |
| Genovis AB (publ.) | 98.04 Million SEK | -51.905% |
| Intervacc AB (publ) | 21.68 Million SEK | -586.983% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -457.653% |
| Active Biotech AB (publ) | 13.4 Million SEK | -1011.478% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | -20.132% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -824.105% |
| Aptahem AB (publ) | 8.99 Million SEK | -1555.266% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -264.517% |
| Kancera AB (publ) | 17.97 Million SEK | -728.446% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -222.516% |
| Fluicell AB (publ) | 8.91 Million SEK | -1570.645% |
| Saniona AB (publ) | 86.08 Million SEK | -73.017% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -2787.515% |
| Biovica International AB (publ) | 34.76 Million SEK | -328.389% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -1176.466% |
| AcouSort AB (publ) | 10.37 Million SEK | -1335.132% |
| Xintela AB (publ) | 14.01 Million SEK | -962.704% |
| Abliva AB (publ) | 16.78 Million SEK | -787.539% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 30.597% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -1187.389% |
| OncoZenge AB (publ) | 1.69 Million SEK | -8666.215% |
| Amniotics AB (publ) | 10.54 Million SEK | -1312.136% |
| 2cureX AB (publ) | 2.93 Million SEK | -4974.549% |
| CombiGene AB (publ) | 4.15 Million SEK | -3483.687% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -3265.07% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 90.488% |
| Camurus AB (publ) | 414.81 Million SEK | 64.096% |
| Corline Biomedical AB | 6.78 Million SEK | -2093.814% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -142.74% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -677.176% |
| I-Tech AB | 16.2 Million SEK | -819.087% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 87.441% |
| Cyxone AB (publ) | 4.69 Million SEK | -3072.944% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -1017.482% |
| Biosergen AB | 5.08 Million SEK | -2828.968% |
| Cantargia AB (publ) | 54.97 Million SEK | -170.944% |
| NextCell Pharma AB | 13.68 Million SEK | -988.008% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -107.29% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -981.489% |
| Nanologica AB (publ) | 79.32 Million SEK | -87.752% |
| SynAct Pharma AB | 51.83 Million SEK | -187.336% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -1773.67% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -2766.98% |
| LIDDS AB (publ) | 3.75 Million SEK | -3865.335% |
| Lipum AB (publ) | 7.53 Million SEK | -1875.829% |
| BioInvent International AB (publ) | 90.45 Million SEK | -64.658% |
| Alzinova AB (publ) | 9.33 Million SEK | -1496.163% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 17.985% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -8202.007% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -705.331% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -3780.615% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -109.424% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 69.111% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -1068.691% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -1951.488% |